Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 12/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.70 |
| ▸ | NPC1 | O15118 | 6/20 | 0.70 |
| ▸ | RAB9A | P51151 | 6/20 | 0.70 |
| ▸ | IKBKB | O14920 | 5/20 | 0.70 |
| ▸ | CASP3 | P42574 | 2/20 | 0.70 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.70 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.70 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.70 |
| ▸ | CDC7 | O00311 | 1/20 | 0.68 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.54 |
| ▸ | MEN1 | O00255 | 6/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.54 |
| ▸ | HPGD | P15428 | 4/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10070140 | 0.85 | MAPT (0.78) | MAPTKDM4ENPC1RAB9AIKBKB | |
| SCHEMBL431794 | 0.85 | MAPT (0.74) | MAPTKDM4ENPC1RAB9AIKBKB | |
| SCHEMBL5196243 | 0.85 | KDM4E (0.61) | MAPTKDM4ENPC1RAB9AIKBKB | |
| SCHEMBL3254787 | 0.85 | MAPT (0.76) | MAPTKDM4ENPC1RAB9AIKBKB | |
| Hydrochloric Acid SCHEMBL8864118 | 0.84 | MAPT (0.72) | MAPTKDM4ENPC1RAB9AIKBKB | |
| SCHEMBL5370617 | 0.84 | MAPT (0.76) | MAPTKDM4ENPC1RAB9AIKBKB | |
| SCHEMBL5195941 | 0.84 | KDM4E (0.76) | MAPTKDM4ENPC1RAB9AIKBKB | |
| SCHEMBL613270 | 0.82 | KDM4E (0.57) | MAPTKDM4ENPC1RAB9AIKBKB | |
| SCHEMBL1531346 | 0.82 | MAPT (1.00) | MAPTKDM4ENPC1RAB9AIKBKB | |
| SCHEMBL27029284 | 0.82 | CDC7 (0.49) | MAPTKDM4ENPC1RAB9AIKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2403857-B1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2013-12-04 | — | — | EP | disclosed |
| US-20120040981-A1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-16 | — | — | US | disclosed |
| EP-2403857-A1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2012-01-11 | — | — | EP | disclosed |
| WO-2010101302-A1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-10 | — | — | WO | disclosed |
| CN-101098852-A | Glycogen phosphorylase inhibitor compounds and pharmaceutical compositions thereof | SMITHKLINE BEECHAM CORP (US) | 2008-01-02 | — | — | CN | disclosed |
| US-20070249670-A1 | Glycogen Phosphorylase Inhibitor Compounds and Pharmaceutical Compositions Thereof | SMITHKLINE BEECHAM CORPORATION (US) | 2007-10-25 | — | — | US | disclosed |
| EP-1812383-A1 | GLYCOGEN PHOSPHORYLASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | Smithkline Beecham Corporation (US) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006052722-A1 | GLYCOGEN PHOSPHORYLASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040981-A1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | CDC7, CDK7, DTYMK | MAPT 2979/4885KDM4E 1319/4885NPC1 2455/4885 |
| US-20070249670-A1 | Glycogen Phosphorylase Inhibitor Compounds and Pharmaceutical Compositions Thereof | PYGM, PYGL, GYS1 | MAPT 1171/4885KDM4E 1970/4885NPC1 1701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.